MELBOURNE, Australia — Patients with type 2 diabetes who are at high risk for or who already have heart failure should not be precluded from receiving dipeptidyl peptidase-4 (DPP-4) inhibitor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results